US 12,071,635 B2
Method for generating T-cell progenitors
Marina Cavazzana, Paris (FR); Isabelle André, Meudon (FR); Chantal Lagresle-Peyrou, Montrouge (FR); Salima Hacein-Bey-Abina, La Garenne Colombes (FR); Christian Reimann, Freiburg (DE); Corinne De Chappedelaine, Paris (FR); and Emmanuelle Six, Saint Geneviève des Bois (FR)
Assigned to ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, Paris (FR); FONDATION IMAGINE-INSTITUT DES MALADIES GÉNÉTIQUES, Paris (FR); UNIVERSITÉCITÉ, Paris (FR); and INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALE (INSERM), Paris (FR)
Appl. No. 15/516,731
Filed by Assistance Publique-Hopitaux de Paris, Paris (FR); Fondation Imagine-Institut Des Maladies Genetiques, Paris (FR); Universtie Paris Descartes, Paris (FR); and Institut National de la Sante et de la Recherche Medicale (INSERM), Paris (FR)
PCT Filed Oct. 5, 2015, PCT No. PCT/EP2015/072889
§ 371(c)(1), (2) Date Apr. 4, 2017,
PCT Pub. No. WO2016/055396, PCT Pub. Date Apr. 14, 2016.
Claims priority of application No. 1459539 (FR), filed on Oct. 6, 2014.
Prior Publication US 2018/0208895 A1, Jul. 26, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/00 (2006.01); C12N 5/0783 (2010.01)
CPC C12N 5/0636 (2013.01) [C12N 2501/42 (2013.01); C12N 2502/1114 (2013.01); C12N 2506/11 (2013.01); C12N 2533/50 (2013.01); C12N 2533/52 (2013.01)] 16 Claims
 
1. An in vitro method of differentiating human cells that express CD34 into T-cell progenitors that express CD7 and optionally CD34, the method comprising culturing human cells that express CD34 for a period of between 3 to 8 days in the presence of:
(i) a medium,
(ii) a Notch ligand immobilized on a support, wherein the Notch ligand comprises a soluble domain of a Delta-like-4 ligand, fused to an Fc region of an IgG protein, and
(iii) a fibronectin fragment comprising an RGDS motif and/or a CS-1 motif,
such that T-cell progenitors that express CD7 and optionally CD34 are obtained.